|
Ikaria (TM) Holdings Incorporated, based in Clinton, New Jersey, is a privately held biotherapeutics company that was formed with the 2007 merger of Ikaria Incorporated, established in 2005, and INO Therapeutics. Ikaria Incorporated's technology was based on metabolic control research conducted by Ikaria Incorporated founder Dr. Mark Roth. INO Therapeutics originally was known for its INOmax (R) nitric oxide pharmaceutical gas, introduced in 1999. It also is developing the Covox (R) carbon monoxide therapeutic agent. Ikaria Holdings focuses on developing critical care therapies. It is pursuing research on metabolic depression treatments. The company is developing and acquiring new drugs, devices, and integrated drug and device systems. It provides business partners with clinical research, device development, manufacturing, marketing, and other services. A manufacturing facility, based in Madison, Wisconsin, produces drug delivery devices.
|